Tseng Yen-Chiang, Tseng Yen-Han, Tang En-Kuei, Goan Yih-Gang
Division of Thoracic Surgery, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung.
Institute of Clinical Medicine, National Yang-Ming University, Taipei.
J Thorac Dis. 2018 May;10(5):E355-E358. doi: 10.21037/jtd.2018.04.114.
Thymomas are enigmatic tumors for which surgical resection is the mainstay of treatment. However, there are still many debates about resected thymomas with pleural recurrence. Repetitive operations for thymomas involving pleural recurrence are still the treatment of choice. Herein, we present a case with a suitable performance status for re-operation with a new application for argon beam coagulation. Both our experience and the currently available evidence suggest that surgical resection could be considered for patients with advanced thymomas, even for patients with locally advanced or Masaoka-Koga stage IV thymomas. Multimodality or multimodal, treatments resulted in better oncological outcomes for these patients. In this case, we proved that the new application of argon beam coagulation for a thymoma patient with pleural recurrence is safe and feasible. Additional evidence should be collected, and patients should be followed to assess long-term benefits.
胸腺瘤是一种神秘的肿瘤,手术切除是其主要治疗方法。然而,对于切除后出现胸膜复发的胸腺瘤仍存在许多争议。对于涉及胸膜复发的胸腺瘤进行重复手术仍是首选治疗方法。在此,我们报告一例具有适合再次手术的身体状况的病例,并介绍氩束凝固术的一种新应用。我们的经验和目前可得的证据均表明,对于晚期胸腺瘤患者,甚至是局部晚期或Masaoka-Koga Ⅳ期胸腺瘤患者,都可考虑手术切除。多模式或多模态治疗能为这些患者带来更好的肿瘤学预后。在本病例中,我们证明了氩束凝固术在胸膜复发胸腺瘤患者中的新应用是安全可行的。应收集更多证据,并对患者进行随访以评估长期获益情况。